{"id":"pandemic-influenza-a-h1n1-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain, redness, or swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated influenza A/H1N1 virus particles that trigger both humoral (antibody) and cell-mediated immune responses. Upon vaccination, the immune system recognizes viral antigens and generates protective antibodies (primarily IgG) and T-cell responses that provide immunity against infection with the H1N1 strain. This prevents or reduces severity of infection if the vaccinated individual is subsequently exposed to the virus.","oneSentence":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against pandemic influenza A/H1N1 virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:59:39.785Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of pandemic influenza A/H1N1 infection"}]},"trialDetails":[{"nctId":"NCT01086904","phase":"PHASE2","title":"Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-11","conditions":"Renal Transplant Recipients, Immunosuppression","enrollment":122},{"nctId":"NCT01192737","phase":"","title":"\"COhort Study on A/H1N1 FLU During PREGnancy\"","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-10","conditions":"Influenza, Pregnancy","enrollment":919},{"nctId":"NCT01499914","phase":"PHASE4","title":"Cohort Study Evaluating the Clinical Effectiveness, Safety and Immunogenicity to the Pandemic Influenza Vaccination","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-11","conditions":"Cystic Fibrosis With Gastrointestinal Manifestation","enrollment":439},{"nctId":"NCT01063608","phase":"PHASE4","title":"Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff.","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-10","conditions":"Influenza A Virus, H1N1 Subtype","enrollment":147},{"nctId":"NCT01394640","phase":"","title":"Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients","status":"COMPLETED","sponsor":"Paolo Corradini","startDate":"2009-10","conditions":"Lymphoma, Multiple Myeloma, Myeloproliferative Disease","enrollment":124},{"nctId":"NCT01051661","phase":"PHASE3","title":"Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-12","conditions":"Influenza","enrollment":6154},{"nctId":"NCT00971906","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Pandemic Influenza","enrollment":660},{"nctId":"NCT01003288","phase":"NA","title":"Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen","status":"COMPLETED","sponsor":"University of Bergen","startDate":"2009-10","conditions":"Healthy","enrollment":255},{"nctId":"NCT03467074","phase":"","title":"Role of Interferon-λ and Vaccine Response","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2014-09-01","conditions":"Vaccine Response Impaired, Allogeneic Stem Cell Transplantation","enrollment":200},{"nctId":"NCT02415842","phase":"","title":"A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-26","conditions":"Immunologic Tests","enrollment":414},{"nctId":"NCT00972517","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-29","conditions":"Influenza","enrollment":245},{"nctId":"NCT00971321","phase":"PHASE2","title":"Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-10","conditions":"Influenza","enrollment":157},{"nctId":"NCT01003418","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-11-17","conditions":"Influenza","enrollment":8},{"nctId":"NCT01014091","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-12-01","conditions":"Influenza","enrollment":60},{"nctId":"NCT01336166","phase":"PHASE2","title":"The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2009-07","conditions":"Influenza","enrollment":480},{"nctId":"NCT01161160","phase":"PHASE2","title":"Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Influenza","enrollment":209},{"nctId":"NCT01059617","phase":"PHASE1","title":"Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-09","conditions":"Influenza","enrollment":133},{"nctId":"NCT00971425","phase":"PHASE3","title":"Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-08","conditions":"Influenza","enrollment":145},{"nctId":"NCT00964158","phase":"PHASE3","title":"Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-10","conditions":"Influenza","enrollment":210},{"nctId":"NCT02143882","phase":"PHASE4","title":"A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).","status":"COMPLETED","sponsor":"Public Health England","startDate":"2014-09","conditions":"Live Attenuated Influenza Vaccine","enrollment":300},{"nctId":"NCT00996853","phase":"","title":"Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-31","conditions":"Influenza","enrollment":9206},{"nctId":"NCT00973895","phase":"PHASE1","title":"VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-08-06","conditions":"Influenza A Virus, H1N1 Subtype, Novel Swine-Origin","enrollment":20},{"nctId":"NCT01037855","phase":"","title":"Observational Study of Safety of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-12","conditions":"Novel Influenza A (H1N1), A New Flu Virus of Swine Origin","enrollment":4028},{"nctId":"NCT00970177","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Pandemic Influenza","enrollment":812},{"nctId":"NCT00992212","phase":"PHASE2","title":"Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Pandemic Influenza Disease","enrollment":418},{"nctId":"NCT00971100","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Pandemic Influenza","enrollment":752},{"nctId":"NCT01160237","phase":"PHASE3","title":"Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Influenza","enrollment":7},{"nctId":"NCT00952419","phase":"PHASE2","title":"A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-08","conditions":"Influenza, Swine-origin A/H1N1 Influenza","enrollment":474},{"nctId":"NCT00959465","phase":"PHASE1, PHASE2","title":"A/H1N1 Immunogenicity and Safety in Adults","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2009-08","conditions":"Influenza, Pandemic Influenza","enrollment":408},{"nctId":"NCT00950456","phase":"","title":"Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2009-11","conditions":"Influenza, Pandemic Influenza","enrollment":3216},{"nctId":"NCT00976469","phase":"PHASE1, PHASE2","title":"A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2009-09","conditions":"Influenza, Pandemic Influenza","enrollment":400},{"nctId":"NCT01032980","phase":"","title":"Post Authorization Safety Study of the Pandemic A/H1N1 Influenza Vaccines in Children and Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12","conditions":"Influenza, Swine-Origin A/H1N1 Influenza Virus","enrollment":3934},{"nctId":"NCT01394614","phase":"","title":"Risk of Narcolepsy Associated With Administration of H1N1 Vaccine","status":"COMPLETED","sponsor":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","startDate":"2011-06","conditions":"Narcolepsy","enrollment":24},{"nctId":"NCT01000831","phase":"PHASE4","title":"Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2009-11","conditions":"Influenza","enrollment":167},{"nctId":"NCT01002040","phase":"PHASE4","title":"Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2010-02","conditions":"HIV Infections, H1N1 Influenza","enrollment":150},{"nctId":"NCT01001026","phase":"PHASE4","title":"Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults","status":"COMPLETED","sponsor":"David Scheifele","startDate":"2009-11","conditions":"H1N1/2009 Influenza","enrollment":156},{"nctId":"NCT01000584","phase":"PHASE4","title":"Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults Receiving Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"David Scheifele","startDate":"2009-11","conditions":"Influenza, H1N1 2009 Influenza","enrollment":309},{"nctId":"NCT01008956","phase":"PHASE2","title":"Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2010-04","conditions":"Influenza","enrollment":""},{"nctId":"NCT01206114","phase":"","title":"Evaluation of the Effectiveness of Vaccination With 2009 H1N1 Vaccines During Influenza Season 2010-11","status":"COMPLETED","sponsor":"Finnish Institute for Health and Welfare","startDate":"2010-09","conditions":"Influenza Caused by the 2009 H1N1 Influenza Virus","enrollment":2351},{"nctId":"NCT01024725","phase":"","title":"Evaluation of Pandemic Vaccination Campaign","status":"COMPLETED","sponsor":"Finnish Institute for Health and Welfare","startDate":"2009-11","conditions":"Influenza Caused by the Novel A(H1N1)v Influenza Virus","enrollment":3518},{"nctId":"NCT00953524","phase":"PHASE2","title":"A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-08","conditions":"Influenza, Swine-origin A/H1N1 Influenza","enrollment":849},{"nctId":"NCT00954798","phase":"PHASE2","title":"A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-08","conditions":"Influenza, Swine-origin A/H1N1 Influenza","enrollment":450},{"nctId":"NCT01053143","phase":"PHASE3","title":"Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-01","conditions":"Influenza, Pandemic Influenza, Influenza A Virus, H1N1 Subtype","enrollment":100},{"nctId":"NCT01089660","phase":"PHASE2","title":"A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-03","conditions":"Influenza, Swine-origin A/H1N1 Influenza","enrollment":202},{"nctId":"NCT00956046","phase":"PHASE2","title":"A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-09","conditions":"Influenza, Swine-origin A/H1N1 Influenza","enrollment":401},{"nctId":"NCT00956202","phase":"PHASE2","title":"A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-08","conditions":"Influenza, Swine-origin A/H1N1 Influenza","enrollment":303},{"nctId":"NCT01298206","phase":"","title":"Case-control Study of Pandemic A/H1N1 Influenza Risk Factors In Lebanon","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2011-10","conditions":"A/H1N1 Influenza, Swine Flu","enrollment":129},{"nctId":"NCT01047202","phase":"PHASE4","title":"Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2009-12","conditions":"Influenza","enrollment":310},{"nctId":"NCT00934245","phase":"PHASE4","title":"Direct and Indirect Protection by Influenza Vaccine Given to Children in India","status":"COMPLETED","sponsor":"Wayne Sullender, M.D.","startDate":"2009-09","conditions":"Influenza","enrollment":4598},{"nctId":"NCT01218685","phase":"","title":"Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2010-04","conditions":"Immunocompromised Patients, Safety of Pandemic Influenza A (H1N1)Vaccine, Immunogenicity of Pandemic Influenza A (H1N1)Vaccine","enrollment":1152},{"nctId":"NCT01111968","phase":"PHASE1","title":"Evaluation of Pandemic Influenza A (H1N1)Candidate Vaccines","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2010-01","conditions":"Influenza","enrollment":266},{"nctId":"NCT01666262","phase":"PHASE1, PHASE2","title":"Phase I/II Safety and Immunogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1) in Healthy Thais","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2009-09","conditions":"Healthy","enrollment":363},{"nctId":"NCT01247415","phase":"","title":"Clinical Investigation on Allergic-like Reactions and Oculo-respiratory Syndrome After the H1N1 Pandemic Vaccine","status":"UNKNOWN","sponsor":"PHAC/CIHR Influenza Research Network","startDate":"2011-01","conditions":"Anaphylaxis, Allergy, Oculorespiratory Syndrome","enrollment":138},{"nctId":"NCT01582633","phase":"PHASE2, PHASE3","title":"Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2012-07","conditions":"Influenza","enrollment":300},{"nctId":"NCT01622491","phase":"","title":"Effectiveness of H1N1 Influenza Vaccines in Manitoba, Canada","status":"UNKNOWN","sponsor":"International Centre for Infectious Diseases, Canada","startDate":"2012-06","conditions":"Influenza, Pneumonia","enrollment":1860},{"nctId":"NCT01079273","phase":"PHASE4","title":"Clinical Study to Evaluate Antibody and Cell Mediated Immunity of A/H1N1 Influenza Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Opera CRO, a TIGERMED Group Company","startDate":"2009-12","conditions":"Influenza","enrollment":7},{"nctId":"NCT01407978","phase":"NA","title":"Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents","status":"COMPLETED","sponsor":"Fluart Innovative Vaccine Ltd, Hungary","startDate":"2009-08","conditions":"Novel 2009 Influenza H1N1, Influenza, Human","enrollment":58},{"nctId":"NCT00989274","phase":"PHASE2","title":"Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1","status":"WITHDRAWN","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2010-06","conditions":"Influenza","enrollment":""},{"nctId":"NCT01066169","phase":"","title":"Vaccination Response in ImmunoCompromised Host. Immune Response After Vaccination Against Pandemic A/H1N1 Influenza","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2009-11","conditions":"HIV","enrollment":104},{"nctId":"NCT01494740","phase":"PHASE2","title":"Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2009-12","conditions":"Influenza","enrollment":312},{"nctId":"NCT01101074","phase":"","title":"Observational Safety and Effectiveness Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-10","conditions":"Influenza A (H1N1)","enrollment":135469},{"nctId":"NCT00971542","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-09","conditions":"Pandemic Influenza","enrollment":778},{"nctId":"NCT01000571","phase":"","title":"Immunogenicity and Safety of Inactivated H1N1 Swine-origin Influenza Monovalent Vaccine in Immunocompromised Children and Young Adults","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2009-10","conditions":"H1N1 Pandemic Flu","enrollment":104},{"nctId":"NCT01040741","phase":"","title":"Observational Safety Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-12","conditions":"Pandemic Influenza A (H1N1), A New Flu Virus of Swine Origin","enrollment":7284},{"nctId":"NCT00952276","phase":"PHASE2","title":"A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Influenza, Swine-origin A/H1N1 Influenza","enrollment":548},{"nctId":"NCT01037829","phase":"","title":"Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-01","conditions":"Influenza","enrollment":4529},{"nctId":"NCT01151644","phase":"PHASE4","title":"Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2010-04","conditions":"Rheumatoid Arthritis, Spondyloarthritis, Systemic Lupus Erythematosus (SLE)","enrollment":5000},{"nctId":"NCT01016548","phase":"PHASE3","title":"Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2009-11","conditions":"Lymphoma, Multiple Myeloma, Influenza A Virus, H1N1 Subtype","enrollment":42},{"nctId":"NCT01055990","phase":"PHASE2","title":"Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients","status":"UNKNOWN","sponsor":"Shanghai Public Health Clinical Center","startDate":"2009-10","conditions":"Virus Diseases, Respiratory Tract Diseases, Respiratory Tract Infections","enrollment":7},{"nctId":"NCT01039623","phase":"NA","title":"Assessment of Safety and Immunogenicity of Intradermal Unadjuvanted Portion of Pandemrix® Via a Microneedle Device With Intramuscular Adjuvanted Pandemrix® as Reference","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2010-01","conditions":"Healthy","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Pandemic influenza A/H1N1 vaccine","genericName":"Pandemic influenza A/H1N1 vaccine","companyName":"Sinovac Biotech Co., Ltd","companyId":"sinovac-biotech-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against pandemic influenza A/H1N1 virus. Used for Prevention of pandemic influenza A/H1N1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}